Boston Orthokeratology (oprifocon A)
Bausch & Lomb · Decision date Dec 16, 2025
What did the FDA decide?
FDA records P010062/S015 as a supplement to PMA P010062, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Dec 16, 2025.
FDA approval order statement
installation and validation of two Large Diameter (Scleral) Lathes at the Bausch + Lomb facility located in Wilmington, MA
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Ophthalmic
- Decision date
- Dec 16, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P010062/S015
- Regulatory pathway
- PMA supplement
- Applicant
- Bausch & Lomb
- Product code
- NUU
- Decision code
- OK30
- Decision date
- Dec 16, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Lens, contact, orthokeratology, overnight.
- Applicant
- Bausch & Lomb
- Product code
- NUU
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P010062/S015 received
Application receipt date recorded by FDA.
P010062/S015 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P010062. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
Other records with product code NUU
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Tianjin MasterVision Technology Co., Ltd. | PMA approval | Aug 5, 2026 | FDA | |
| Euclid Vision Corporation | PMA supplement | Apr 2, 2026 | FDA | |
| Euclid Vision Corporation | PMA supplement | Mar 12, 2026 | FDA | |
| Euclid Vision Corporation | PMA supplement | Mar 6, 2026 | FDA | |
| Contamac, Ltd. | PMA approval | Feb 10, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Bausch & Lomb
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1400 N. Goodman St., Rochester, NY, 14603
Sources and methodology
- Original FDA record: P010062/S015
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


